A Phase 2 interventional study of SC0032 and Placebo in Refractory Chronic Cough and Unexplained Chronic Cough, sponsored by Sensory Cloud, Inc.. Recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Sensory Cloud, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Chronic Cough with a site in United Kingdom — 4 open to participants now, 5 under way, none of them phase 3. Chronic Cough · United Kingdom.
Among the 36 studies in Chronic Cough with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2026, is one of 15 in phase 2, and was the 34th registered.
142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.
Browse Chronic Cough studies →4 of the 36 studies in Chronic Cough with a site in United Kingdom are open now. Recruiting first, the newest first:
Trevi Therapeutics · Sites in United Kingdom, Canada
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 30–70 · Healthy volunteers
Hull University Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 7 · Phase 4 2
First in 2008; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 104 interventional studies indexed under Chronic Cough.
Median enrollment 100 across the 29 interventional studies, 60 across the 7 observational. Of the 28 that completed or were terminated, 12 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sensory Cloud, Inc. as lead sponsor.
Sensory Cloud, Inc. has 1 study filed under Chronic Cough — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Cough with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07690059Sensory Cloud, Inc.A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough | 2027-01 |
| NCT07671924Trevi TherapeuticsThe Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Chronic Cough with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized placebo-controlled, parallel-arm study to determine the safety and efficacy of SC0032 in participants with RCC
There are three parts to this study and an optional fourth part:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of myocardial infarction or other cardiac disorders as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sodium Chloride
Device: Placebo
Magnesium Chloride
Combination Product: SC0032
Magnesium Chloride
Sodium Chloride
Difference in mean % change from baseline in 24-hour cough frequency using the mean of Days -8 to -2 for last 7 days of baseline vs the mean of Days 13-19 last 7 days of the treatment period, using the HYFE continuous cough monitor).
Linear mixed model with log-transformed daily cough frequency as response variable, fixed effect for treatment, and random effects for participants; fitted model yields point estimate and 95% CI estimate of placebo-adjusted treatment effect
Time frame: Day -8 to Day 19.
Time to onset of response based on median time (in days) from start of treatment to first day when mean treatment effect ≥30%, based on cumulative daily averages using the HYFE continuous cough monitor) from Day 1 to Day 20.
Kaplan-Meier survival analysis to estimate median time to response (with 95% confidence intervals); log-rank test to compare response times of the treatment groups Cox proportional hazards model with adjustment for mean baseline cough frequency will yield a hazard ratio and 95% CIs.
Time frame: From Day 1 to Day 20
Determine duration of response (≥30% reduction relative to baseline) from baseline (mean of Days -8 to -2) vs the Follow up period (mean of Days 22-28, 29-35, 36-42 and 43-49).
Linear mixed model with log-transformed daily cough frequency as response variable, fixed effect for treatment, and random effects for participants; fitted model yields point estimate and 95% CI estimate of placebo-adjusted treatment effect over the follow up period. The differences in the proportion of responders during each week of the follow up period will be evaluated using a Fisher's exact test.
Time frame: Day -8 to Day 49
Change in number of cough bouts per 24-hour period, defined using inter-cough gap thresholds of 2.0s, from Day -14 to -2 and Day 1 to Day 21.
Linear mixed model with log-transformed daily bout frequency as response variable, fixed effect for treatment, and random effects for participants; fitted model yields point estimate and 95% CI estimate of placebo-adjusted treatment effect.
Time frame: From Day -14 to Day 21
Change in Leicester Cough questionnaire (LCQ) score on Day 0 vs Day 21. A 19-item, patient-completed health-related quality of life (HRQoL) for chronic cough. Each item is rated on a 7-point Likert scale (1-7), with higher score indicates better QoL.
The change from baseline will be analysed using an Analysis of Covariance (ANCOVA) model. The model will include baseline measurement (Visit 2 - Day 0) as a covariate and Treatment as the main factor; and a Baseline\*Treatment interaction term will be investigated. Type III sums of squares will be used. The model will yield adjusted least-squares means for Placebo and SC0032, along with the placebo-SC0032 treatment difference with corresponding 95% confidence intervals. A p value will also be presented for the difference.
Time frame: Day 0 to Day 21
Change in Cough Severity Visual Analogue Scale (CS-VAS) score (0-100mm line anchored with "no cough" at 0 mm and "worst cough imaginable" at 100 mm) from Day 0 and Day 21.
The change from baseline will be analysed using an Analysis of Covariance (ANCOVA) model. The model will include baseline measurement (Visit 2) as a covariate and Treatment as the main factor; and a Baseline\*Treatment interaction term will be investigated. Type III sums of squares will be used. The model will yield adjusted least-squares means for Placebo and SC0032, along with the placebo-SC0032 treatment difference with corresponding 95% confidence intervals. A p value will also be presented for the difference.
Time frame: Day 0 to Day 21
Change in Patient Global Impression of Severity 5-point score (PGI-S) score from Day 0 and Day 21. Response options typically range from "None" to "Severe", with higher scores indicating greater symptom severity.
The distribution of PGI-S at Visit 3 (Day 21) between Placebo and SC0032 will be compared using a Cochran-Mantel-Haenszel test. An ordered (proportional odds) logistic regression model will be used to quantify treatment effects and estimate odds ratios (at Visit 3, adjusted for PGIS score at Visit 2 (Day 0) ) with 95% confidence intervals.
Time frame: Day 0 to Day 21
Change in categorical Patient Global Impression of Change (PGI-C) score from Day 0 and Day 21 analyzed as the proportion of participants achieving improvement on the 7-point scale. Response options range from "Very much improved" to "Very much worse."
The difference in proportion of participants achieving improvement will be analysed using a Fisher's exact test (or CMH if appropriate). A binary logistic regression model (or ordinal equivalent) will be used to quantify treatment effects and estimate odds ratios with 95% confidence intervals.
Time frame: Day 0 to Day 21
Change in Newcastle Laryngeal Hypersensitivity Questionnaire (LHQ) score from Day 0 and Day 21. A 14-item tool measuring subjective laryngeal sensory symptoms. Items are rated on a 7-point Likert scale, with lower scores indicating greater severity.
The change from baseline will be analysed using an Analysis of Covariance (ANCOVA) model. The model will include baseline measurement (Visit 2) as a covariate and Treatment as the main factor; and a Baseline\*Treatment interaction term will be investigated. Type III sums of squares will be used. The model will yield adjusted least-squares means for Placebo and SC0032, along with the placebo-SC0032 treatment difference with corresponding 95% confidence intervals. A p value will also be presented for the difference.
Time frame: Day 0 to Day 21
Change in mean daily cough from Day -8 to -2 vs Day 13-19 in Daily Cough Numeric Rating Scale (CS-NRS), an 11-point PRO rating severity of their cough over the past 24 hours. The scale ranges from 0 ("no cough") to 10 ("worst possible cough").
Linear mixed model as per Item 1 (primary endpoint).
Time frame: Day -8 to Day 19
Report incidence of treatment-emergent adverse events (TEAEs).
Descriptive summary of incidence of treatment-emergent adverse events by treatment according to SOC and Preferred Term; n (%) frequency for duration of study.
Time frame: Day -14 to Day 49
Report the severity of TEAEs.
Descriptive summary of severity (number and % of mild, moderate, or severe) of treatment-emergent adverse events by treatment for duration of study according to SOC and Preferred Term; n (%) frequency.
Time frame: Day -14 to Day 49
Change from in FEV₁ and FVC from Day -14 to Day 49 by treatment group.
Descriptive change distributions by treatment group.
Time frame: Day -14 to Day 49
Report number and % of participants with ≥1 serious adverse event (SAE) for duration of study.
Descriptive summary by treatment according to SOC and Preferred Term; n (%) frequency.
Time frame: Day -14 to Day 49
Difference in mean % change from baseline in 24-hour cough frequency. The mean of Days -8 to -2 (baseline) vs the mean of Days 1-7 and 8-12 (Parallel Arm period).
The same model used in the primary objective (Item 1) will be applied.
Time frame: Day -8 to Day 12
Determine the duration of response of SC0032 vs placebo by identifying the last week post-treatment when the mean treatment effect remains ≥20% reduction and ≥50% reduction.
Difference in mean % change in cough frequency between Day 22-28, 29-35, 36-42, 43-49 (Follow-up Period) and mean % change in cough frequency for Day -8 to -2 (baseline), SC0032 vs placebo. Descriptive and inferential comparison (as per item 3; for ≥20% reduction and ≥50% reduction thresholds.
Time frame: Day -8 to Day 49
Define time to onset of effect based on cough bouts analyzed as per Objective 2 ((≥30% reduction), time course of treatment as per Objective 3 (baseline (mean of Days -8 to -2) vs the Follow up period (mean of Days 22-28, 29-35, 36-42 and 43-49).
Time to onset will be analysed as per Objective 2, time course of treatment as per Objective 3 and the cough to bout ratio will be analysed using a linear mixed model (as per the primary).
Time frame: Day -8 to Day 49
Change in number, duration, and coughs per bout across definitions using linear mixed model with treatment group as a fixed effect, study day as a repeated-measure and random effects for participants between Day -14 to -2 and Day 1 to Day 21.
Compare number, duration, and coughs per bout across definitions using linear mixed model with treatment group as a fixed effect, study day as a repeated-measure and random effects for participants.
Time frame: Day -14 to Day 21
Change in PRO's (CS-VAS, PGI-S, LCQ, LHQ) from Day -14 to Day 0 and Day 21 to Day 49.
Descriptive summaries and change from Visit 1 (Day -14) to Visit 2 (Day 0) and from Visit 3 (Day 21) to Visit 4 (Day 49). All ANCOVAs as per Item 5. Except PGI-S which will be analyzed as per Item 7, along with descriptive summaries.
Time frame: Day -14 to Day 49
The proportion of participants with a clinically meaningful change in PGI-C at Visit 4 -Day 49.
Descriptive summaries of actual values at Visit 4 (Day 49) by treatment group, as per Item 8.
Time frame: Day -14 to Day 49
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 6 months after the start.
Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.